Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Klaudyna Fidyt, Marta Krawczyk, Monika Pepek, Katsiaryna Marhelava, Agnieszka Kraft, Malgorzata Bobrowicz, Aleksandra Kusowska, Joanna Barankiewicz, Przemyslaw Juszczynski, Michal Smida, Myron Czuczman, Francisco Hernandez-Ilizaliturri, Malgorzata Firczuk, Magdalena Winiarska

Blood (2022) 140 (Supplement 1): 10273–10274.

https://doi.org/10.1182/blood-2022-162292

Published: 2022

Journal Articles

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M. Foss, Youn H. Kim, H. Miles Miles Prince, Timothy M. Kuzel, Costas K. Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic

Blood (2022) 140 (Supplement 1): 1491–1492.

https://doi.org/10.1182/blood-2022-166916

Published: 2022

Journal Articles

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss

Blood (2022) 140 (Supplement 1): 6577–6578.

https://doi.org/10.1182/blood-2022-167564

Published: 2022

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Blood (2019) 134 (Supplement_1): 1524.

https://doi.org/10.1182/blood-2019-129024

Published: 2019

Journal Articles

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2019) 134 (Supplement_1): 919.

https://doi.org/10.1182/blood-2019-123694

Published: 2019

Journal Articles

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Blood (2019) 134 (Supplement_1): 923.

https://doi.org/10.1182/blood-2019-122756

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Blood (2019) 134 (Supplement_1): 4092.

https://doi.org/10.1182/blood-2019-123083

Published: 2019

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson

Blood (2016) 128 (21): 2510–2516.

https://doi.org/10.1182/blood-2016-06-718106

Published: 2016

Journal Articles

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

Lawrence D. Kaplan, MD, Sin-Ho Jung, PhD, Wendy Stock, MD, Nancy L. Bartlett, MD, Brandelyn Pitcher, MS, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD, Noreen Fulton, Eric D. Hsi, MD, David D Hurd, MD, Myron Czuczman, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 337.

https://doi.org/10.1182/blood.V126.23.337.337

Published: 2015

Journal Articles

The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity

Ping-Chiao Tsai, Naveen Bangia, Scott Olejniczak, Francisco J. Hernandez-Ilizaliturri, Myron Czuczman

Blood (2008) 112 (11): 2607.

https://doi.org/10.1182/blood.V112.11.2607.2607

Published: 2008

Journal Articles

The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphoma (B-NHL) Cells

Francisco J. Hernandez-Ilizaliturri, MD, Sapna Khubchandani, MD, Scott H. Olejniczak, PhD, Paul Hosking, MD, Elizabeth Gruber, MS, Myron Czuczman, MD

Blood (2008) 112 (11): 605.

https://doi.org/10.1182/blood.V112.11.605.605

Published: 2008

Journal Articles

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Swaminathan Padmanabhan, MD, Anjana Elefante, PharmD, Prakash Varadarajan, MD, Minoo Battiwalla, MD, Arvinder Bir, MD, Theresa Hahn, PhD, Shannon Smiley, MD, Francisco J. Hernandez-Illizalitturi, MD, Loretta Miner, RNP, Alice Mohr, RNP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Philip McCarthy, Jr., MD, Myron Czuczman, MD

Blood (2007) 110 (11): 5130.

https://doi.org/10.1182/blood.V110.11.5130.5130

Published: 2007

Journal Articles

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Thomas E. Witzig, MD, Craig B. Reeder, MD, Jonathan Polikoff, MD, Naveed M. Chowhan, MD, Isaac Esseessee, MD, Richard Greenberg, MD, Hermant Patel, MD, Davood Vafai, MD, Peter H. Wiernik, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Myron Czuczman, MD

Blood (2007) 110 (11): 2572.

https://doi.org/10.1182/blood.V110.11.2572.2572

Published: 2007

Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD

Blood (2006) 108 (11): 2711.

https://doi.org/10.1182/blood.V108.11.2711.2711

Published: 2006

Journal Articles

Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL).

Maria Alma Rodriguez, MD, Anna Ter Veer, MS, Auayporn Nademanee, M.D., Joyce Niland, Ph.D., Eva Lepisto, MS, Michelle Kho, MSc, Ann LaCasce, M.D., Jane Carrie Weeks, M.D., Myron Czuczman, M.D., Michael Millenson, M.D., Jonathan Friedberg, M.D., Andrew D. Zelenetz, M.D.

Blood (2006) 108 (11): 3328.

https://doi.org/10.1182/blood.V108.11.3328.3328

Published: 2006

Journal Articles

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Anas Younes, MD, Julie M. Vose, MD, Andrew D. Zelenetz, MD, PhD, Mitchell R. Smith, MD, PhD, Howard Burris, MD, Stephen Ansell, MD, PhD, Jerry Klein, PhD, Elizabeth Kumm, MS, Myron Czuczman, MD

Blood (2005) 106 (11): 489.

https://doi.org/10.1182/blood.V106.11.489.489

Published: 2005

Journal Articles

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

Myron Czuczman, M.D., Bryan R. Leigh, M.D., Thomas E. Witzig, M.D., Julie M. Vose, M.D., Anas Younes, M.D., Baha Alkuzweny, Ph.D., Anne Larocca, Ph.D., Xianjun Cao, M.S., Aron Thall, Ph.D.

Blood (2004) 104 (11): 3292.

https://doi.org/10.1182/blood.V104.11.3292.3292

Published: 2004

NARROW

CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity

The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphoma (B-NHL) Cells

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL).

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only